ValuEngine lowered shares of Diplomat Pharmacy (NYSE:DPLO) from a hold rating to a sell rating in a research report sent to investors on Wednesday.

A number of other equities research analysts also recently weighed in on the company. Morgan Stanley upped their target price on Diplomat Pharmacy from $16.00 to $21.00 and gave the stock an equal weight rating in a research report on Tuesday, July 3rd. Leerink Swann restated an outperform rating and issued a $33.00 target price on shares of Diplomat Pharmacy in a research report on Friday, June 22nd. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating and six have given a buy rating to the company. The stock has a consensus rating of Hold and an average price target of $26.64.

DPLO opened at $18.61 on Wednesday. The company has a market capitalization of $1.42 billion, a price-to-earnings ratio of 22.15 and a beta of 1.12. The company has a debt-to-equity ratio of 0.58, a current ratio of 0.91 and a quick ratio of 0.63. Diplomat Pharmacy has a 1-year low of $14.50 and a 1-year high of $28.74.

Diplomat Pharmacy (NYSE:DPLO) last released its earnings results on Monday, August 6th. The company reported $0.17 earnings per share for the quarter, missing analysts’ consensus estimates of $0.23 by ($0.06). The firm had revenue of $1.42 billion during the quarter, compared to analyst estimates of $1.42 billion. Diplomat Pharmacy had a return on equity of 7.86% and a net margin of 0.06%. The business’s revenue for the quarter was up 25.8% on a year-over-year basis. During the same quarter last year, the company earned $0.25 earnings per share. analysts predict that Diplomat Pharmacy will post 0.83 EPS for the current fiscal year.

In other news, Director Philip R. Hagerman sold 209,367 shares of the stock in a transaction on Thursday, September 13th. The stock was sold at an average price of $19.07, for a total transaction of $3,992,628.69. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Philip R. Hagerman sold 57,500 shares of the stock in a transaction on Tuesday, September 11th. The shares were sold at an average price of $19.21, for a total value of $1,104,575.00. The disclosure for this sale can be found here. 24.70% of the stock is currently owned by corporate insiders.

Several large investors have recently made changes to their positions in DPLO. SG Americas Securities LLC acquired a new stake in shares of Diplomat Pharmacy during the 1st quarter valued at $104,000. Meadow Creek Investment Management LLC acquired a new stake in Diplomat Pharmacy during the 1st quarter valued at $107,000. Glen Harbor Capital Management LLC acquired a new stake in Diplomat Pharmacy during the 1st quarter valued at $129,000. UBS Group AG raised its stake in Diplomat Pharmacy by 186.4% during the 1st quarter. UBS Group AG now owns 8,491 shares of the company’s stock valued at $171,000 after purchasing an additional 5,526 shares during the period. Finally, D.A. Davidson & CO. acquired a new stake in Diplomat Pharmacy during the 2nd quarter valued at $215,000. Institutional investors own 81.04% of the company’s stock.

Diplomat Pharmacy Company Profile

Diplomat Pharmacy, Inc operates as an independent specialty pharmacy in the United States. The company stocks, dispenses, and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. It also provides specialty infusion pharmacy, patient care coordination, clinical, compliance and persistency program, patient financial assistance, specialty pharmacy training/consulting, benefits investigation, prior authorization, risk evaluation and medication strategy, retail specialty, and hub services, as well as clinical and administrative support services to hospitals and health systems.

Read More: How to Use the New Google Finance Tool

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Diplomat Pharmacy (NYSE:DPLO)

Receive News & Ratings for Diplomat Pharmacy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diplomat Pharmacy and related companies with's FREE daily email newsletter.